{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-199157","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.173973+00:00","generated_at":"2026-05-15T00:15:41.236476+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"low","headline":"Aldeyra provides reproxalap trial endpoint estimates and FDA stance in corporate overview","bullets":["Standardized treatment estimates and confidence intervals disclosed for reproxalap dry eye disease clinical trials primary endpoints.","Aldeyra summarizes its interpretations of FDA positions on primary endpoints and its own positions in the NDA.","Presentation is a voluntary Reg FD disclosure; no financial results or guidance included."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-199157","json":"https://secwatch.observer/filing/0001193125-26-199157.json","markdown":"https://secwatch.observer/filing/0001193125-26-199157.md","text":"https://secwatch.observer/filing/0001193125-26-199157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526199157/0001193125-26-199157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526199157/aldx-20260501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:15:41.236476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}